News & Media
FDA Approves QBiotics’ Veterinary Anti-Cancer Treatment Stelfonta
Pet Insight
19 Nov 2020
19 Nov 2020
Read More 
QBiotics' STELFONTA Receives FDA Approval for Canine Mast cell Tumours
BioSpace.com
18 Nov 2020
18 Nov 2020
Read More
FDA Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs
U.S. Food and Drug Administration
16 Nov 2020
16 Nov 2020
Read More
New canine cancer treatment available
Vet Practice Magazine
22 Jun 2020
22 Jun 2020
Read More
Promising New Cancer Treatment for Dogs with Mast Cell Tumours
Australian Dog Lover
17 Jun 2020
17 Jun 2020
Read More
QBiotics commercialises first tigilanol tiglate pharmaceutical product
Biotech Dispatch
30 Apr 2020
30 Apr 2020
Read More
Dr Boreham’s Crucible: Why unlisted QBiotics has a good chance of cracking the cancer market
Stockhead.com
15 Mar 2020
15 Mar 2020
Read More
European approval for QBiotics tigilanol tiglate
Biotech Dispatch
21 Jan 2020
21 Jan 2020
Read More
Anticancer candidate trialled in solid tumours
Lab Online
10 Jan 2020
10 Jan 2020
Read More
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
BioSpace.com
12 Dec 2019
12 Dec 2019
Read More
QBiotics updates on publication of tigilanol tiglate trial results
Biotech Dispatch
10 Dec 2019
10 Dec 2019
Read More
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours
BioSpace.com
09 Dec 2019
09 Dec 2019
Read More
Page 2 of 2